Personalized cancer vaccine from Moderna and Merck shows breakthrough in melanoma
TL;DR
Moderna and Merck reported a personalized mRNA cancer vaccine used with Keytruda that reduced melanoma recurrence and spread in a trial of more than 1,000 patients, with five-year data from earlier results showing about a 50% drop in recurrence and a 59% drop in spread versus Keytruda alone; if approved, thousands of melanoma patients could benefit in the first years, and trials in other cancers (lung, bladder, kidney, pancreatic, stomach) are ongoing with results expected in the coming years.
- Moderna, Merck breakthrough could usher in wave of cancer vaccines CNN
- Cancer vaccine from Moderna, Merck shows promise in late-stage trial; both stocks soar CNBC
- It now seems possible to vaccinate against cancer The Economist
- Moderna’s Shift to Cancer Company Lifts Stock Up 177% The New York Times
- Opinion | A cancer vaccine would be a miracle of science — and the free market The Washington Post
Want the full story? Read the original reporting
Read on CNN